Olga Smolentseva

BIONTECH - BUY | USD308 Omicron-adapted booster sets a precedent for EUA approval based on preclinical data

FDA approves bivalent booster setting the precedent of preclinical data use
Another lawsuit targeting mRNA technology, but we do not expect a significant impact on net revenues
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Olga Smolentseva

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch